No Data
Many Still Looking Away From Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513)
Easton Biopharmaceuticals Gets Registration Certificate for Dihydroxypropyl Theophylline Injection
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Chengdu Easton Biopharmaceuticals (688513.SH): is currently constructing an AI drug development assistance platform.
On March 3rd, GELONGHUI reported that Chengdu Easton Biopharmaceuticals (688513.SH) stated on the interactive platform that the company has always focused on the application potential of AI large models as efficiency tools, encouraging employees to improve work efficiency through the rational use of AI tools. At the same time, the company is also building an AI-assisted platform for drug development, planning to gradually launch functional modules within the year. The planned functionalities include virtual screening (molecular docking), similarity search, substructure search, molecular generation, patent filtering, and molecular drugability assessment.
Yuandong Biology: Yuandong Biology: 2024 Annual Results Express Announcement
Yuandong Biology: 2024 Annual Results Express Announcement
Some Shareholders Feeling Restless Over Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) P/E Ratio